U.S. License Holder:
Tanvex BioPharma, Inc.
Date of License:
aBLA accepted by FDA October-2021
Last Update:
Nov-30-2023
FDA-Approved Indications
TX-05 (trastuzumab) is not FDA-approved. An aBLA has been submitted to the FDA.